Amplity Health’s Post

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG

Pfizer has a long and storied history of scientific breakthroughs when it comes to both blood disorders and breast cancer. Over the next week, we’re showcasing some of our latest progress in both fields, through more than 100 presentations at #ASH2024 and #SABCS24. At the 2024 American Society of Hematology Annual Meeting in San Diego, Pfizer will highlight our growing hematology portfolio and pipeline, showcasing our progress in advancing treatments for blood cancers, rare blood disorders, and hemophilia. At the San Antonio Breast Cancer Symposium, our teams will present data that reaffirm our CDK4/6 inhibitor as a first-line standard of care for breast cancer, sharing progress on next-generation therapies, and studies aimed at transforming outcomes for patients. I’m incredibly proud of the relentless dedication of our teams, whose work continues to set new standards of care, bring hope, and deliver breakthroughs that change patients’ lives. Learn more about these breakthroughs: https://lnkd.in/ehr2atNR

𝗠𝗲𝗿𝗰𝗸, 𝗞𝗲𝗹𝘂𝗻 𝘁𝗿𝘂𝗺𝗽𝗲𝘁 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶-𝗧𝗥𝗢𝗣𝟮 𝗔𝗗𝗖 Merck and Kelun LifeSciences (Pvt)Ltd-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or metastatic triple-negative breast cancer, the anti-TROP2 ADC sacituzumab tirumotecan (previously known as SKB264/MK-2870) reduced patients’ risk of disease progression or death (PFS) by 69% compared with chemotherapy. Additionally, patients’ overall risk of death (OS) was reduced by 47%. Both results were statistically significant. https://lnkd.in/drDavMAf

Day 2 of the Inaugural AACR Oncology Industry Partnering Event was just as informative as Day 1! During a session with the FDA, key messages were shared about the future of cancer treatment. Here are some of the highlights: 🔹 increase in multi-modality approaches to targets, including small molecule, ADC, and radioligand therapy. 🔹 A multi-target approach is necessary to address cancer. 🔹 Immunologically cold tumors, such as prostate and pancreas, are particularly challenging to combat. 🔹 Confirmatory trials are required to start in a timely manner for accelerated approvals. 🔹 Dose optimization prior to phase III is crucial. 🔹 Response rate remains a critical endpoint for drug approval decisions. 🔹 Are clinical trial designs becoming too complicated? #pragmatica

We are pleased to share clinical program updates for our mutant-selective PI3Ka inhibitor STX-478 that underscore our commitment to advancing precision oncology. At #SABCS24, we are presenting updated data from our Phase 1/2 study of STX-478. The results highlight robust PI3Kα pathway inhibition, favorable safety, and a clear dose-response relationship. These findings reinforce STX-478’s potential to transform outcomes for patients with a variety of solid tumors. Additionally, we have entered into a new clinical trial collaboration with #Pfizer to evaluate Pfizer’s investigative selective-CDK4 inhibitor, in combination with STX-478 and fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer in the frontline metastatic setting. Together with our partners, we are dedicated to shaping the future of cancer therapy by delivering innovative, targeted solutions for those who need them most. Learn more: https://bit.ly/4fbaw13

When 20% of patients don’t succeed with conventional cancer treatments, this is where we come into the picture! Having personally witnessed the devastating effects of inoperable cancer, I'm dedicated to transforming cancer care. At IntraGel Therapeutics we're pioneering minimally invasive interventional oncology to provide safe, life-saving alternatives for those who need them most. Watch this short video to learn more about our mission and how we're bringing new hope to millions of cancer patients #CancerTreatment #Oncology #Pharma #IntraGel

#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/eC_H9R8N #OvarianCancer #CancerTesting #Oncology

Where, how and why can complex issues like circulating tumor DNA, and by extension, minimal residual disease help us to drive novel trial designs that are more patient friendly and concurrently can expedite the safety and efficacy evaluations of novel therapeutics? In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Warl Harb and Patrick Kelly to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Listen to the full episode: https://ow.ly/cgS730sHl2M

Partnership to Develop Next-Gen Radioligand Medicine for Rare Cancers!! 🤝 🎯 !! Collaboration between Sanofi, Radiomedix, Inc. and Orano Med focuses specifically on the late-stage project, AlphaMedix (212Pb-DOTAMTATE), which currently is being evaluated for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. AlphaMedixT is a targeted alpha therapy (TAT) which consists of a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb) that serves as an in vivo generator of alpha particles. #AlphaMedix has recently been granted Breakthrough Therapy Designation in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from the US FDA for patients who are naïve to peptide-receptor radionuclide therapy. #sanofi #radiomedix #oranomed #competitiveintelligence #pharma #cancer

🔬💡 Update from Merck! 💡🔬 Merck has ended its Phase III trial of anti-TIGIT antibody vibostolimab with Keytruda for high-risk melanoma due to high dropout rates from immune-related adverse events. Patients will now receive Keytruda alone. 📉 Keytruda is still a vital treatment for metastatic and unresectable melanoma. Merck is also pursuing a Phase III study with Moderna's V940 for high-risk melanoma. 🌟 Despite this setback, Merck remains dedicated to improving cancer care. 💪 #Merck #Keytruda #CancerResearch #Immunotherapy #ClinicalTrials #Oncology 🚀🔬